OKYO.L Sygnały na żywo | Maksymalizuj zyski z Getagraph.com

Live Chart Being Loaded With Signals

Commentary (19 geg. 2023 @ 18:35):

OKYO Pharma Limited, a preclinical biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom...

Stats
Dzisiejszy wolumen	19 575.00
Średni wolumen	538 135
Kapitalizacja rynkowa	23.22M
EPS	£0 ( 2023-12-28 )
Last Dividend	£0 ( N/A )
Next Dividend	£0 ( N/A )
P/E	-1.400
ATR14	£0.371 (26.50%)

Wolumen Korelacja

Długi: 0.26 (neutral)

Krótki: -0.60 (weak negative)

Signal:(35.253) Neutral

OKYO Pharma Ltd Korelacja

10 Najbardziej pozytywne korelacje

10 Najbardziej negatywne korelacje

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

OKYO Pharma Ltd Korelacja - Waluta/Towar

-0.56
( weak negative )

0.06
( neutral )

0.00
( neutral )

-0.46
( neutral )

0.49
( neutral )

OKYO Pharma Ltd Finanse

Annual	2022
Przychody:	£0
Zysk brutto:	£0 (0.00 %)
EPS:	£-0.00420

FY	2022
Przychody:	£0
Zysk brutto:	£0 (0.00 %)
EPS:	£-0.00420

FY	2021
Przychody:	£0.00
Zysk brutto:	£0.00 (0.00 %)
EPS:	£-0.00446

FY	2020
Przychody:	£0.00
Zysk brutto:	£0.00 (0.00 %)
EPS:	£-0.00200

Financial Reports:

No articles found.

OKYO Pharma Ltd

OKYO Pharma Limited, a preclinical biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead product includes OK-101 for the treatment of dry eye disease. The company is also developing OK-201, a bovine adrenal medulla, lipidated-peptide preclinical analogue candidate for the treatment of neuropathic ocular pain. OKYO Pharma Limited was incorporated in 2007 and is headquartered in London, the United Kingdom.